Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Jun 28, 2022

SEC Form 4/A — Form 4/A

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-04-14

Reporting Person: PURA VIDA INVESTMENTS, LLC (10% Owner)
Reporting Person: Kamen Efrem (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-14	Common Stock	P	30790	$1.227	Acquired	7381237	Indirect
2022-04-14	Common Stock	P	92370	$1.26	Acquired	7473607	Indirect
2022-04-14	Common Stock	P	19210	$1.227	Acquired	8475033	Indirect
2022-04-14	Common Stock	P	57630	$1.26	Acquired	8532663	Indirect

Footnotes

F1: Aggregate number of shares purchased on the same date at difference prices.

F2: Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.19 to $1.27, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Securities and Exchange Commission staff (the "Staff"), Issuer or any security holder, upon request.

F3: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.

F4: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.

F5: Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.235 to $1.305, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Staff, Issuer or any security holder, upon request.